Sarepta TherapeuticsSRPT
SRPT
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
38% more funds holding in top 10
Funds holding in top 10: 8 [Q3] → 11 (+3) [Q4]
24% more first-time investments, than exits
New positions opened: 72 | Existing positions closed: 58
15% more call options, than puts
Call options by funds: $211M | Put options by funds: $184M
0.37% less ownership
Funds ownership: 92.35% [Q3] → 91.99% (-0.37%) [Q4]
1% less funds holding
Funds holding: 452 [Q3] → 448 (-4) [Q4]
2% less repeat investments, than reductions
Existing positions increased: 153 | Existing positions reduced: 156
3% less capital invested
Capital invested by funds: $11B [Q3] → $10.7B (-$310M) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$75
29%
downside
Avg. target
$134
26%
upside
High target
$202
90%
upside
4 analyst ratings
2 positive
50%
0 neutral
0%
2 negative
50%
HC Wainwright & Co. Mitchell Kapoor 32% 1-year accuracy 57 / 176 met price target | 29%downside $75 | Sell Reiterated | 13 Feb 2025 |
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 126 / 333 met price target | 29%downside $75 | Sell Reiterated | 30 Jan 2025 |
Needham Gil Blum 22% 1-year accuracy 36 / 167 met price target | 90%upside $202 | Buy Reiterated | 27 Jan 2025 |
Piper Sandler Biren Amin 27% 1-year accuracy 6 / 22 met price target | 71%upside $182 | Overweight Maintained | 27 Nov 2024 |
Financial journalist opinion
Based on 8 articles about SRPT published over the past 30 days
Positive
Market Watch
3 days ago
20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'
The co-chief investment officers at Neuberger Berman see a new dynamic in the stock market as investors move on from inflation worries.
Positive
Zacks Investment Research
4 days ago
Down -8.52% in 4 Weeks, Here's Why Sarepta Therapeutics (SRPT) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Sarepta Therapeutics (SRPT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Neutral
Business Wire
1 week ago
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has closed on a $600 million senior secured revolving credit facility with a bank syndicate. "Sarepta's financial strength and the positive outlook for our business provide us with the flexibility to use non-dilutive financing by establishing a revolving credit facility. It supplements our strong balance sheet and allows for contingent.
Neutral
Business Wire
1 week ago
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2024 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 26, 2025. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2024 financial results. The event will be webcast live under the investor relations section of Sarepta's website a.
Neutral
Business Wire
1 week ago
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT) announced on November 26, 2024, has now closed. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions. Summary Financial Terms Upon closing, Arrowhead receives a $500 milli.
Positive
The Motley Fool
1 week ago
2 Growth Stocks to Buy Hand Over Fist in February
Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in other industries -- even in healthcare, a sector some investors might consider boring.
Positive
Zacks Investment Research
2 weeks ago
Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?
Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.
Neutral
Business Wire
3 weeks ago
Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced positive topline results from Part 2 of EMBARK (Study SRP-9001-301), a global, randomized, double-blind, placebo-controlled, Phase 3 clinical study of ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy. Crossover-treated patients, those who received a placebo in Part 1 and.
Positive
Seeking Alpha
1 month ago
Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely
Sarepta Therapeutics' Elevidys for DMD shows growing revenue potential, with management targeting >$3bn of total revenues in 2025, up 68% from 2024, led by the gene therapy. Despite past valuation concerns, Sarepta's current market cap of $11.4bn is justified, with potential for a >50% gain by YE25. Elevidys' high price and mixed clinical results raise concerns, but totality of evidence suggests it may be the best available treatment for DMD, with no immediate rivals.
Neutral
Business Wire
1 month ago
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2024 net product revenue and cash on hand as of December 31, 2024, as part of its presentation today at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. Financial Update* (preliminary and unaudited): Total net product revenue of $638.2 million for the fourth quarter and $1.79 bi.
Charts implemented using Lightweight Charts™